Skip to main content
SpringerLink
Log in
Book cover

Glucocorticoid Signaling pp 83–96Cite as

Clinical Perspective: What Do Addison and Cushing Tell Us About Glucocorticoid Action?

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 872))

Abstract

This chapter is distinct from the others in its clinical subject matter. I will attempt to outline the major points of interest in glucocorticoids clinically. To aid the illustration in the evaluation of a patient with Cushing disease I have created a case study.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Cassidy F, Ritchie JC, Verghese K, Carroll BJ. Dexamethasone metabolism in dexamethasone suppression test suppressors and nonsuppressors. Biol Psychiatry. 2000;47:677–80.

    Article  CAS  PubMed  Google Scholar 

  2. He HC, et al. Retroperitoneal adrenal-sparing surgery for the treatment of Cushing’s syndrome caused by adrenocortical adenoma: 8-year experience with 87 patients. World J Surg. 2012;36:1182–8. doi:10.1007/s00268-012-1509-0.

    Article  PubMed  Google Scholar 

  3. Hawn MT, Cook D, Deveney C, Sheppard BC. Quality of life after laparoscopic bilateral adrenalectomy for Cushing’s disease. Surgery 2002;132:1064–8; discussion 1068–9. doi:10.1067/msy.2002.128482.

  4. Nelson DH, Meakin JW, Thorn GW. ACTH-producing pituitary tumors following adrenalectomy for Cushing’s syndrome. Ann Intern Med. 1960;52:560–9.

    Article  CAS  PubMed  Google Scholar 

  5. Vu L, Theodore PR. Localization of a corticotropin-secreting tumor by thoracoscopic pulmonary venous sampling. N Engl J Med. 2005;353:851–2. doi:10.1056/NEJMc050486.

    Article  CAS  PubMed  Google Scholar 

  6. Colao A, et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366:914–24. doi:10.1056/NEJMoa1105743.

    Article  CAS  PubMed  Google Scholar 

  7. Bertagna X, et al. LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014;99:1375–83. doi:10.1210/jc.2013-2117.

    Article  CAS  PubMed  Google Scholar 

  8. Yombi JC, Maiter D, Belkhir L, Nzeusseu A, Vandercam B. Iatrogenic Cushing’s syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol. 2008;27 Suppl 2:S79–82. doi:10.1007/s10067-008-1022-x.

    Article  PubMed  Google Scholar 

  9. Kumar S, Singh RJ, Reed AM, Lteif AN. Cushing’s syndrome after intra-articular and intradermal administration of triamcinolone acetonide in three pediatric patients. Pediatrics. 2004;113:1820–4.

    Article  PubMed  Google Scholar 

  10. O’Sullivan MM, Rumfeld WR, Jones MK, Williams BD. Cushing’s syndrome with suppression of the hypothalamic-pituitary-adrenal axis after intra-articular steroid injections. Ann Rheum Dis. 1985;44:561–3.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Bernecker C, West TB, Mansmann W, Scherbaum WA, Willenberg HS. Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy. 2 case reports and a review of the literature. Exp Clin Endocrinol Diabetes. 2012;120:125–7. doi:10.1055/s-0031-1297993.

    Article  CAS  PubMed  Google Scholar 

  12. Yeh SS, Schuster MW. Megestrol acetate in cachexia and anorexia. Int J Nanomedicine. 2006;1:411–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Freda PU, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:894–904. doi:10.1210/jc.2010-1048.

    Article  CAS  PubMed  Google Scholar 

  14. Molitch ME, Russell EJ. The pituitary “incidentaloma”. Ann Intern Med. 1990;112:925–31.

    Article  CAS  PubMed  Google Scholar 

  15. Van Staa TP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48:3224–9. doi:10.1002/art.11283.

    Article  PubMed  Google Scholar 

  16. Randazzo ME, Grossrubatscher E, Dalino Ciaramella P, Vanzulli A, Loli P. Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary. 2012;15:193–201. doi:10.1007/s11102-011-0306-3.

    Article  CAS  PubMed  Google Scholar 

  17. Annane D, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862–71.

    Article  CAS  PubMed  Google Scholar 

  18. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350:1629–38. doi:10.1056/NEJMoa020266.

    Article  CAS  PubMed  Google Scholar 

  19. Sprung CL, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358:111–24. doi:10.1056/NEJMoa071366.

    Article  CAS  PubMed  Google Scholar 

  20. Arlt W, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341:1013–20. doi:10.1056/NEJM199909303411401.

    Article  CAS  PubMed  Google Scholar 

  21. Alkatib AA, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94:3676–81. doi:10.1210/jc.2009-0672.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Metabolism and Lipid Research, Department of Internal Medicine, Washington University School of Medicine, 660 S Euclid Avenue, Campus Box 8127, St. Louis, MO, 63110, USA

    Charles Harris M.D., Ph.D.

Authors
  1. Charles Harris M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles Harris M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Nutritional Science & Toxicology, University of California Berkeley, Berkeley, California, USA

    Jen-Chywan Wang

  2. Division of Endocrinology Metabolism & Lipid Research, Department of Internal Medicine, Washington University School of Medicine Division of Endocrinology, St. Louis, Missouri, USA

    Charles Harris

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Harris, C. (2015). Clinical Perspective: What Do Addison and Cushing Tell Us About Glucocorticoid Action?. In: Wang, JC., Harris, C. (eds) Glucocorticoid Signaling. Advances in Experimental Medicine and Biology, vol 872. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2895-8_4

Download citation

Publish with us

Policies and ethics

Search

Navigation